Baicalin ameliorates neuroinflammation-induced depressive-like behavior through inhibition of toll-like receptor 4 expression via the PI3K/AKT/FoxO1 pathway
Baicalin, which is isolated from Radix Scutellariae, possesses strong biological activities including an anti-inflammation property. Recent studies have shown that the anti-inflammatory effect of baicalin is linked to toll-like receptor 4 (TLR4), which participates in pathological changes of central...
Saved in:
| Published in | Journal of neuroinflammation Vol. 16; no. 1; pp. 95 - 21 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
08.05.2019
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Baicalin, which is isolated from Radix Scutellariae, possesses strong biological activities including an anti-inflammation property. Recent studies have shown that the anti-inflammatory effect of baicalin is linked to toll-like receptor 4 (TLR4), which participates in pathological changes of central nervous system diseases such as depression. In this study, we explored whether baicalin could produce antidepressant effects via regulation of TLR4 signaling in mice and attempted to elucidate the underlying mechanisms.
A chronic unpredictable mild stress (CUMS) mice model was performed to explore whether baicalin could produce antidepressant effects via the inhibition of neuroinflammation. To clarify the role of TLR4 in the anti-neuroinflammatory efficacy of baicalin, a lipopolysaccharide (LPS) was employed in mice to specially activate TLR4 and the behavioral changes were determined. Furthermore, we used LY294002 to examine the molecular mechanisms of baicalin in regulating the expression of TLR4 in vivo and in vitro using western blot, ELISA kits, and immunostaining. In the in vitro tests, the BV2 microglia cell lines and primary microglia cultures were pretreated with baicalin and LY292002 for 1 h and then stimulated 24 h with LPS. The primary microglial cells were transfected with the forkhead transcription factor forkhead box protein O 1 (FoxO1)-specific siRNA for 5 h and then co-stimulated with baicalin and LPS to investigate whether FoxO1 participated in the effect of baicalin on TLR4 expression.
The administration of baicalin (especially 60 mg/kg) dramatically ameliorated CUMS-induced depressive-like symptoms; substantially decreased the levels of interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) in the hippocampus; and significantly decreased the expression of TLR4. The activation of TLR4 by the LPS triggered neuroinflammation and evoked depressive-like behaviors in mice, which were also alleviated by the treatment with baicalin (60 mg/kg). Furthermore, the application of baicalin significantly increased the phosphorylation of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and FoxO1. The application of baicalin also promoted FoxO1 nuclear exclusion and contributed to the inhibition of the FoxO1 transactivation potential, which led to the downregulation of the expression of TLR4 in CUMS mice or LPS-treated BV2 cells and primary microglia cells. However, prophylactic treatment of LY294002 abolished the above effects of baicalin. In addition, we found that FoxO1 played a vital role in baicalin by regulating the TLR4 and TLR4-mediating neuroinflammation triggered by the LPS via knocking down the expression of FoxO1 in the primary microglia.
Collectively, these results demonstrate that baicalin ameliorated neuroinflammation-induced depressive-like behaviors through the inhibition of TLR4 expression via the PI3K/AKT/FoxO1 pathway. |
|---|---|
| AbstractList | Baicalin, which is isolated from Radix Scutellariae, possesses strong biological activities including an anti-inflammation property. Recent studies have shown that the anti-inflammatory effect of baicalin is linked to toll-like receptor 4 (TLR4), which participates in pathological changes of central nervous system diseases such as depression. In this study, we explored whether baicalin could produce antidepressant effects via regulation of TLR4 signaling in mice and attempted to elucidate the underlying mechanisms.
A chronic unpredictable mild stress (CUMS) mice model was performed to explore whether baicalin could produce antidepressant effects via the inhibition of neuroinflammation. To clarify the role of TLR4 in the anti-neuroinflammatory efficacy of baicalin, a lipopolysaccharide (LPS) was employed in mice to specially activate TLR4 and the behavioral changes were determined. Furthermore, we used LY294002 to examine the molecular mechanisms of baicalin in regulating the expression of TLR4 in vivo and in vitro using western blot, ELISA kits, and immunostaining. In the in vitro tests, the BV2 microglia cell lines and primary microglia cultures were pretreated with baicalin and LY292002 for 1 h and then stimulated 24 h with LPS. The primary microglial cells were transfected with the forkhead transcription factor forkhead box protein O 1 (FoxO1)-specific siRNA for 5 h and then co-stimulated with baicalin and LPS to investigate whether FoxO1 participated in the effect of baicalin on TLR4 expression.
The administration of baicalin (especially 60 mg/kg) dramatically ameliorated CUMS-induced depressive-like symptoms; substantially decreased the levels of interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) in the hippocampus; and significantly decreased the expression of TLR4. The activation of TLR4 by the LPS triggered neuroinflammation and evoked depressive-like behaviors in mice, which were also alleviated by the treatment with baicalin (60 mg/kg). Furthermore, the application of baicalin significantly increased the phosphorylation of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and FoxO1. The application of baicalin also promoted FoxO1 nuclear exclusion and contributed to the inhibition of the FoxO1 transactivation potential, which led to the downregulation of the expression of TLR4 in CUMS mice or LPS-treated BV2 cells and primary microglia cells. However, prophylactic treatment of LY294002 abolished the above effects of baicalin. In addition, we found that FoxO1 played a vital role in baicalin by regulating the TLR4 and TLR4-mediating neuroinflammation triggered by the LPS via knocking down the expression of FoxO1 in the primary microglia.
Collectively, these results demonstrate that baicalin ameliorated neuroinflammation-induced depressive-like behaviors through the inhibition of TLR4 expression via the PI3K/AKT/FoxO1 pathway. Abstract Background Baicalin, which is isolated from Radix Scutellariae, possesses strong biological activities including an anti-inflammation property. Recent studies have shown that the anti-inflammatory effect of baicalin is linked to toll-like receptor 4 (TLR4), which participates in pathological changes of central nervous system diseases such as depression. In this study, we explored whether baicalin could produce antidepressant effects via regulation of TLR4 signaling in mice and attempted to elucidate the underlying mechanisms. Methods A chronic unpredictable mild stress (CUMS) mice model was performed to explore whether baicalin could produce antidepressant effects via the inhibition of neuroinflammation. To clarify the role of TLR4 in the anti-neuroinflammatory efficacy of baicalin, a lipopolysaccharide (LPS) was employed in mice to specially activate TLR4 and the behavioral changes were determined. Furthermore, we used LY294002 to examine the molecular mechanisms of baicalin in regulating the expression of TLR4 in vivo and in vitro using western blot, ELISA kits, and immunostaining. In the in vitro tests, the BV2 microglia cell lines and primary microglia cultures were pretreated with baicalin and LY292002 for 1 h and then stimulated 24 h with LPS. The primary microglial cells were transfected with the forkhead transcription factor forkhead box protein O 1 (FoxO1)-specific siRNA for 5 h and then co-stimulated with baicalin and LPS to investigate whether FoxO1 participated in the effect of baicalin on TLR4 expression. Results The administration of baicalin (especially 60 mg/kg) dramatically ameliorated CUMS-induced depressive-like symptoms; substantially decreased the levels of interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) in the hippocampus; and significantly decreased the expression of TLR4. The activation of TLR4 by the LPS triggered neuroinflammation and evoked depressive-like behaviors in mice, which were also alleviated by the treatment with baicalin (60 mg/kg). Furthermore, the application of baicalin significantly increased the phosphorylation of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and FoxO1. The application of baicalin also promoted FoxO1 nuclear exclusion and contributed to the inhibition of the FoxO1 transactivation potential, which led to the downregulation of the expression of TLR4 in CUMS mice or LPS-treated BV2 cells and primary microglia cells. However, prophylactic treatment of LY294002 abolished the above effects of baicalin. In addition, we found that FoxO1 played a vital role in baicalin by regulating the TLR4 and TLR4-mediating neuroinflammation triggered by the LPS via knocking down the expression of FoxO1 in the primary microglia. Conclusion Collectively, these results demonstrate that baicalin ameliorated neuroinflammation-induced depressive-like behaviors through the inhibition of TLR4 expression via the PI3K/AKT/FoxO1 pathway. Background Baicalin, which is isolated from Radix Scutellariae, possesses strong biological activities including an anti-inflammation property. Recent studies have shown that the anti-inflammatory effect of baicalin is linked to toll-like receptor 4 (TLR4), which participates in pathological changes of central nervous system diseases such as depression. In this study, we explored whether baicalin could produce antidepressant effects via regulation of TLR4 signaling in mice and attempted to elucidate the underlying mechanisms. Methods A chronic unpredictable mild stress (CUMS) mice model was performed to explore whether baicalin could produce antidepressant effects via the inhibition of neuroinflammation. To clarify the role of TLR4 in the anti-neuroinflammatory efficacy of baicalin, a lipopolysaccharide (LPS) was employed in mice to specially activate TLR4 and the behavioral changes were determined. Furthermore, we used LY294002 to examine the molecular mechanisms of baicalin in regulating the expression of TLR4 in vivo and in vitro using western blot, ELISA kits, and immunostaining. In the in vitro tests, the BV2 microglia cell lines and primary microglia cultures were pretreated with baicalin and LY292002 for 1 h and then stimulated 24 h with LPS. The primary microglial cells were transfected with the forkhead transcription factor forkhead box protein O 1 (FoxO1)-specific siRNA for 5 h and then co-stimulated with baicalin and LPS to investigate whether FoxO1 participated in the effect of baicalin on TLR4 expression. Results The administration of baicalin (especially 60 mg/kg) dramatically ameliorated CUMS-induced depressive-like symptoms; substantially decreased the levels of interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) in the hippocampus; and significantly decreased the expression of TLR4. The activation of TLR4 by the LPS triggered neuroinflammation and evoked depressive-like behaviors in mice, which were also alleviated by the treatment with baicalin (60 mg/kg). Furthermore, the application of baicalin significantly increased the phosphorylation of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and FoxO1. The application of baicalin also promoted FoxO1 nuclear exclusion and contributed to the inhibition of the FoxO1 transactivation potential, which led to the downregulation of the expression of TLR4 in CUMS mice or LPS-treated BV2 cells and primary microglia cells. However, prophylactic treatment of LY294002 abolished the above effects of baicalin. In addition, we found that FoxO1 played a vital role in baicalin by regulating the TLR4 and TLR4-mediating neuroinflammation triggered by the LPS via knocking down the expression of FoxO1 in the primary microglia. Conclusion Collectively, these results demonstrate that baicalin ameliorated neuroinflammation-induced depressive-like behaviors through the inhibition of TLR4 expression via the PI3K/AKT/FoxO1 pathway. Baicalin, which is isolated from Radix Scutellariae, possesses strong biological activities including an anti-inflammation property. Recent studies have shown that the anti-inflammatory effect of baicalin is linked to toll-like receptor 4 (TLR4), which participates in pathological changes of central nervous system diseases such as depression. In this study, we explored whether baicalin could produce antidepressant effects via regulation of TLR4 signaling in mice and attempted to elucidate the underlying mechanisms.BACKGROUNDBaicalin, which is isolated from Radix Scutellariae, possesses strong biological activities including an anti-inflammation property. Recent studies have shown that the anti-inflammatory effect of baicalin is linked to toll-like receptor 4 (TLR4), which participates in pathological changes of central nervous system diseases such as depression. In this study, we explored whether baicalin could produce antidepressant effects via regulation of TLR4 signaling in mice and attempted to elucidate the underlying mechanisms.A chronic unpredictable mild stress (CUMS) mice model was performed to explore whether baicalin could produce antidepressant effects via the inhibition of neuroinflammation. To clarify the role of TLR4 in the anti-neuroinflammatory efficacy of baicalin, a lipopolysaccharide (LPS) was employed in mice to specially activate TLR4 and the behavioral changes were determined. Furthermore, we used LY294002 to examine the molecular mechanisms of baicalin in regulating the expression of TLR4 in vivo and in vitro using western blot, ELISA kits, and immunostaining. In the in vitro tests, the BV2 microglia cell lines and primary microglia cultures were pretreated with baicalin and LY292002 for 1 h and then stimulated 24 h with LPS. The primary microglial cells were transfected with the forkhead transcription factor forkhead box protein O 1 (FoxO1)-specific siRNA for 5 h and then co-stimulated with baicalin and LPS to investigate whether FoxO1 participated in the effect of baicalin on TLR4 expression.METHODSA chronic unpredictable mild stress (CUMS) mice model was performed to explore whether baicalin could produce antidepressant effects via the inhibition of neuroinflammation. To clarify the role of TLR4 in the anti-neuroinflammatory efficacy of baicalin, a lipopolysaccharide (LPS) was employed in mice to specially activate TLR4 and the behavioral changes were determined. Furthermore, we used LY294002 to examine the molecular mechanisms of baicalin in regulating the expression of TLR4 in vivo and in vitro using western blot, ELISA kits, and immunostaining. In the in vitro tests, the BV2 microglia cell lines and primary microglia cultures were pretreated with baicalin and LY292002 for 1 h and then stimulated 24 h with LPS. The primary microglial cells were transfected with the forkhead transcription factor forkhead box protein O 1 (FoxO1)-specific siRNA for 5 h and then co-stimulated with baicalin and LPS to investigate whether FoxO1 participated in the effect of baicalin on TLR4 expression.The administration of baicalin (especially 60 mg/kg) dramatically ameliorated CUMS-induced depressive-like symptoms; substantially decreased the levels of interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) in the hippocampus; and significantly decreased the expression of TLR4. The activation of TLR4 by the LPS triggered neuroinflammation and evoked depressive-like behaviors in mice, which were also alleviated by the treatment with baicalin (60 mg/kg). Furthermore, the application of baicalin significantly increased the phosphorylation of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and FoxO1. The application of baicalin also promoted FoxO1 nuclear exclusion and contributed to the inhibition of the FoxO1 transactivation potential, which led to the downregulation of the expression of TLR4 in CUMS mice or LPS-treated BV2 cells and primary microglia cells. However, prophylactic treatment of LY294002 abolished the above effects of baicalin. In addition, we found that FoxO1 played a vital role in baicalin by regulating the TLR4 and TLR4-mediating neuroinflammation triggered by the LPS via knocking down the expression of FoxO1 in the primary microglia.RESULTSThe administration of baicalin (especially 60 mg/kg) dramatically ameliorated CUMS-induced depressive-like symptoms; substantially decreased the levels of interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) in the hippocampus; and significantly decreased the expression of TLR4. The activation of TLR4 by the LPS triggered neuroinflammation and evoked depressive-like behaviors in mice, which were also alleviated by the treatment with baicalin (60 mg/kg). Furthermore, the application of baicalin significantly increased the phosphorylation of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and FoxO1. The application of baicalin also promoted FoxO1 nuclear exclusion and contributed to the inhibition of the FoxO1 transactivation potential, which led to the downregulation of the expression of TLR4 in CUMS mice or LPS-treated BV2 cells and primary microglia cells. However, prophylactic treatment of LY294002 abolished the above effects of baicalin. In addition, we found that FoxO1 played a vital role in baicalin by regulating the TLR4 and TLR4-mediating neuroinflammation triggered by the LPS via knocking down the expression of FoxO1 in the primary microglia.Collectively, these results demonstrate that baicalin ameliorated neuroinflammation-induced depressive-like behaviors through the inhibition of TLR4 expression via the PI3K/AKT/FoxO1 pathway.CONCLUSIONCollectively, these results demonstrate that baicalin ameliorated neuroinflammation-induced depressive-like behaviors through the inhibition of TLR4 expression via the PI3K/AKT/FoxO1 pathway. |
| ArticleNumber | 95 |
| Audience | Academic |
| Author | Ma, Zhan-Qiang Zhang, Ru-Yi Wang, Si-Qi Zhao, Qin-Wen Su, Jing Xu, Li-Xing Ma, Shi-Ping Guo, Li-Ting Deng, Xue-Yang Ji, Zhou-Ye |
| Author_xml | – sequence: 1 givenname: Li-Ting surname: Guo fullname: Guo, Li-Ting – sequence: 2 givenname: Si-Qi surname: Wang fullname: Wang, Si-Qi – sequence: 3 givenname: Jing surname: Su fullname: Su, Jing – sequence: 4 givenname: Li-Xing surname: Xu fullname: Xu, Li-Xing – sequence: 5 givenname: Zhou-Ye surname: Ji fullname: Ji, Zhou-Ye – sequence: 6 givenname: Ru-Yi surname: Zhang fullname: Zhang, Ru-Yi – sequence: 7 givenname: Qin-Wen surname: Zhao fullname: Zhao, Qin-Wen – sequence: 8 givenname: Zhan-Qiang surname: Ma fullname: Ma, Zhan-Qiang – sequence: 9 givenname: Xue-Yang surname: Deng fullname: Deng, Xue-Yang – sequence: 10 givenname: Shi-Ping orcidid: 0000-0003-1695-7811 surname: Ma fullname: Ma, Shi-Ping |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31068207$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAUhSNURH_gAdigSGzYpOPfxNkgtRWFUSuVRVlbN_b1jEsSD04ytO_Cw-LplNKpEPLC1vV3jn3tc5jt9aHHLHtLyTGlqpwNlNWVKAitCyrSQr3IDmglWMFILfaerPezw2G4IYQzWbJX2T6npFSMVAfZr1PwBlrf59Bh60OEEYe8xykG37sWug5GH_rC93YyaHOLq4jD4NdYtP475g0uYZ1k-biMYVosc98vfeM3mjy4fAxtuwUjGlyNCRQ53m49ErL2kJSYf53zi9nJxfXsPNxe0XwF4_In3L3OXjpoB3zzMB9l384_XZ99KS6vPs_PTi4LI0syFsoKZI4yLmoHHBpOmAWrrBSqpqRuSieVBTCNISWxggKasiQVUucck67iR9l862sD3OhV9B3EOx3A6_tCiAsNcfSmRU0r6komGzC1Ekhso9BxKevGNaaynCSvj1uv1dR0aA32Y4R2x3R3p_dLvQhrXUpSESaTwYcHgxh-TDiMuvODwbaFHsM0aMY4rQVXFU_o-2foTZhin54qUayipRRE_KUWkBpIvxrSuWZjqk-kKqWUim-o439QaVjsvEm5cz7VdwTvnjb62OGfbCWAbgETwzBEdI8IJXqTX73Nr0751Zv8apU01TON8eN9AtNtfPsf5W_k8vZP |
| CitedBy_id | crossref_primary_10_1038_s41380_021_01327_3 crossref_primary_10_1016_j_phymed_2023_154686 crossref_primary_10_1016_j_archoralbio_2021_105219 crossref_primary_10_1016_j_neuropharm_2020_108336 crossref_primary_10_3389_fphar_2023_1168990 crossref_primary_10_1007_s12640_020_00292_z crossref_primary_10_1016_j_gene_2020_144817 crossref_primary_10_3389_fimmu_2020_581673 crossref_primary_10_1002_ptr_7696 crossref_primary_10_1016_j_jad_2023_04_117 crossref_primary_10_1016_j_microc_2024_112324 crossref_primary_10_1016_j_phrs_2020_104890 crossref_primary_10_3389_fphar_2022_955672 crossref_primary_10_1016_j_bbi_2025_02_011 crossref_primary_10_3390_molecules27165083 crossref_primary_10_1016_j_bbi_2025_02_010 crossref_primary_10_1186_s13048_022_00965_7 crossref_primary_10_1016_j_gene_2024_148966 crossref_primary_10_1016_j_jep_2022_116038 crossref_primary_10_4110_in_2022_22_e21 crossref_primary_10_2147_DDDT_S480077 crossref_primary_10_1177_0145561320986058 crossref_primary_10_3389_fphar_2022_855964 crossref_primary_10_3390_antiox11050947 crossref_primary_10_1002_iid3_707 crossref_primary_10_1007_s00011_022_01557_3 crossref_primary_10_1016_j_brainresbull_2023_110843 crossref_primary_10_1007_s00213_021_05895_8 crossref_primary_10_1016_j_bbr_2023_114299 crossref_primary_10_3390_ijms25189930 crossref_primary_10_3389_fphar_2022_927419 crossref_primary_10_1016_j_jep_2022_115977 crossref_primary_10_1177_1934578X211016643 crossref_primary_10_1007_s13205_024_04182_5 crossref_primary_10_1016_j_jad_2022_11_018 crossref_primary_10_3389_fphar_2021_586788 crossref_primary_10_1016_j_brainresbull_2020_06_015 crossref_primary_10_1016_j_heliyon_2023_e17125 crossref_primary_10_1016_j_chemosphere_2024_143466 crossref_primary_10_3390_cimb46020082 crossref_primary_10_3390_ijms25105085 crossref_primary_10_3389_fphar_2020_556845 crossref_primary_10_1007_s11655_024_3767_8 crossref_primary_10_1016_j_biopha_2023_115338 crossref_primary_10_1016_j_bbamcr_2024_119675 crossref_primary_10_1002_smll_202407685 crossref_primary_10_1016_j_pbb_2021_173285 crossref_primary_10_3390_antiox14030259 crossref_primary_10_1155_2022_3263446 crossref_primary_10_1016_j_phrs_2020_104759 crossref_primary_10_1055_s_0043_1773797 crossref_primary_10_3390_antiox11091811 crossref_primary_10_1186_s12974_020_02040_8 crossref_primary_10_1016_j_jep_2023_116659 crossref_primary_10_4168_aair_2021_13_6_882 crossref_primary_10_1177_17590914231181037 crossref_primary_10_1016_j_prmcm_2024_100550 crossref_primary_10_1039_D1TB01054A crossref_primary_10_1016_j_phrs_2024_107112 crossref_primary_10_1007_s10529_022_03334_y crossref_primary_10_1016_j_jare_2024_07_015 crossref_primary_10_1007_s10528_025_11085_4 crossref_primary_10_1080_13880209_2024_2415666 crossref_primary_10_3389_fimmu_2022_1006434 crossref_primary_10_1016_j_hsr_2022_100020 crossref_primary_10_1016_j_ynstr_2020_100268 crossref_primary_10_1155_2022_3321099 crossref_primary_10_3390_medicina59040741 crossref_primary_10_4103_MJBL_MJBL_275_23 crossref_primary_10_1186_s13567_024_01352_4 crossref_primary_10_3389_fphar_2021_694475 crossref_primary_10_1016_j_prmcm_2023_100326 crossref_primary_10_1155_2020_8951907 crossref_primary_10_1155_2021_1805147 crossref_primary_10_1016_j_fsi_2020_09_014 crossref_primary_10_1016_j_jbc_2025_108230 crossref_primary_10_1002_cbdv_202400892 crossref_primary_10_1016_j_biopha_2024_117611 crossref_primary_10_3390_molecules27217521 crossref_primary_10_1016_j_jpba_2021_114064 crossref_primary_10_1021_acs_chemrestox_1c00317 crossref_primary_10_1007_s00213_021_05784_0 crossref_primary_10_1016_j_applanim_2024_106471 crossref_primary_10_3892_mmr_2023_13129 crossref_primary_10_2174_1386207326666230116124532 crossref_primary_10_1080_13880209_2025_2467374 crossref_primary_10_2174_0113816128269432240103052108 crossref_primary_10_1016_j_bbr_2019_112053 crossref_primary_10_1016_j_intimp_2024_112554 crossref_primary_10_1080_01616412_2021_2022913 crossref_primary_10_1080_08923973_2020_1808985 crossref_primary_10_3390_ijms251910259 crossref_primary_10_1016_j_phymed_2024_155686 crossref_primary_10_1016_j_micres_2023_127440 crossref_primary_10_1016_j_lfs_2020_118107 crossref_primary_10_1016_j_bbi_2020_11_008 crossref_primary_10_1111_cns_14291 crossref_primary_10_1155_2023_2507683 crossref_primary_10_3389_fphar_2022_999962 crossref_primary_10_1002_ptr_7402 crossref_primary_10_1126_sciadv_adi8287 crossref_primary_10_1007_s12035_023_03737_6 crossref_primary_10_1016_j_bbi_2020_11_002 crossref_primary_10_1016_j_expneurol_2022_114225 crossref_primary_10_1007_s11011_025_01536_7 crossref_primary_10_3390_cells13050423 crossref_primary_10_1016_j_cclet_2021_10_029 crossref_primary_10_1016_j_phrs_2024_107300 crossref_primary_10_3389_fphar_2022_937075 crossref_primary_10_1039_D1RA07553E crossref_primary_10_1111_cns_14740 crossref_primary_10_1080_13880209_2020_1779318 crossref_primary_10_15252_embj_2022111867 crossref_primary_10_1016_j_brainresbull_2024_111008 crossref_primary_10_1016_j_dci_2024_105194 crossref_primary_10_1007_s10787_021_00895_8 crossref_primary_10_1016_j_ijbiomac_2025_140445 crossref_primary_10_3390_ijms241210402 crossref_primary_10_1021_acs_jafc_5c00300 crossref_primary_10_1016_j_pmip_2024_100128 crossref_primary_10_1016_j_ejphar_2024_177091 crossref_primary_10_1016_j_phymed_2024_155669 crossref_primary_10_1186_s12974_022_02400_6 crossref_primary_10_1002_cbdv_202401093 crossref_primary_10_1016_j_jpsychires_2025_02_012 crossref_primary_10_3389_fphar_2022_986436 crossref_primary_10_1016_j_ejphar_2024_176427 crossref_primary_10_1136_lupus_2023_000943 crossref_primary_10_1039_D3FO02065G crossref_primary_10_1155_jfbc_8113079 crossref_primary_10_1007_s00210_023_02639_7 crossref_primary_10_1007_s12272_020_01292_5 crossref_primary_10_1016_j_jad_2024_03_017 crossref_primary_10_1016_j_cej_2025_159988 crossref_primary_10_1111_and_14216 crossref_primary_10_2174_0929867328666210820115259 crossref_primary_10_3389_fphar_2021_767333 crossref_primary_10_3389_fphar_2022_849513 crossref_primary_10_1016_j_joim_2023_07_002 crossref_primary_10_3389_fphar_2022_843412 crossref_primary_10_1186_s12974_020_01886_2 crossref_primary_10_3389_fphar_2022_853496 crossref_primary_10_1016_j_bbr_2022_113769 crossref_primary_10_1016_j_lfs_2019_117151 crossref_primary_10_1007_s43032_024_01562_3 crossref_primary_10_1016_j_biopha_2021_112599 crossref_primary_10_3389_fcell_2020_553728 crossref_primary_10_1186_s12974_024_03312_3 crossref_primary_10_2174_1570159X18666200114125628 crossref_primary_10_1016_j_ijbiomac_2021_06_118 crossref_primary_10_1016_j_intimp_2022_108788 crossref_primary_10_1093_toxres_tfaa107 crossref_primary_10_1038_s41598_025_85286_7 crossref_primary_10_3389_fphar_2019_01271 crossref_primary_10_1016_j_expneurol_2024_114937 crossref_primary_10_1016_j_jad_2025_03_021 crossref_primary_10_1007_s40263_024_01123_x crossref_primary_10_1016_j_intimp_2021_108024 crossref_primary_10_3136_fstr_FSTR_D_24_00202 crossref_primary_10_1016_j_intimp_2023_110595 crossref_primary_10_3390_ph17121704 crossref_primary_10_1016_j_brainresbull_2020_08_016 crossref_primary_10_1002_med_22012 crossref_primary_10_1111_bph_15261 crossref_primary_10_1155_2022_2112359 crossref_primary_10_1016_j_ejphar_2022_174993 crossref_primary_10_1186_s12974_022_02492_0 crossref_primary_10_1016_j_bbr_2021_113245 crossref_primary_10_1155_2020_4751349 crossref_primary_10_3389_fphar_2024_1426769 crossref_primary_10_1186_s13578_020_00388_1 crossref_primary_10_1016_j_intimp_2022_108532 crossref_primary_10_1016_j_foodres_2022_112384 crossref_primary_10_3390_molecules28052080 crossref_primary_10_3390_biomedicines13010232 crossref_primary_10_1080_21655979_2022_2038448 crossref_primary_10_2174_1568026620666200924115611 crossref_primary_10_3390_brainsci11111514 crossref_primary_10_3389_fphar_2024_1425094 crossref_primary_10_1002_jbio_202400468 crossref_primary_10_1016_j_brainres_2023_148567 crossref_primary_10_1177_10738584251316558 crossref_primary_10_3389_fphar_2022_848355 crossref_primary_10_3389_fphar_2024_1370619 crossref_primary_10_3390_antiox9030216 crossref_primary_10_1016_j_bbr_2023_114440 crossref_primary_10_1016_j_bbi_2021_03_016 crossref_primary_10_1016_j_biopha_2023_116012 crossref_primary_10_2174_1871527319666200715102430 crossref_primary_10_1016_j_bbih_2022_100562 crossref_primary_10_1016_j_intimp_2024_112330 crossref_primary_10_1080_21655979_2022_2053032 crossref_primary_10_1016_j_biopha_2022_112668 crossref_primary_10_1186_s12906_020_03135_8 crossref_primary_10_3390_brainsci15030238 crossref_primary_10_1016_j_intimp_2021_107725 crossref_primary_10_1097_WNR_0000000000002088 crossref_primary_10_1007_s11011_022_01067_5 crossref_primary_10_1021_acschemneuro_0c00120 crossref_primary_10_1186_s12951_022_01598_0 crossref_primary_10_1016_j_jep_2023_116487 crossref_primary_10_1016_j_jep_2024_118943 crossref_primary_10_1038_s42003_019_0600_6 crossref_primary_10_1016_j_fbio_2024_104587 crossref_primary_10_1016_j_biopha_2023_114464 crossref_primary_10_1016_j_intimp_2024_113375 crossref_primary_10_3389_fphar_2024_1313871 crossref_primary_10_1016_j_chmed_2023_02_002 crossref_primary_10_1016_j_jep_2021_114586 crossref_primary_10_1080_10408398_2022_2099808 crossref_primary_10_3390_molecules28186501 crossref_primary_10_3390_ph14010065 crossref_primary_10_1016_j_heliyon_2024_e27307 crossref_primary_10_1016_j_taap_2024_117043 crossref_primary_10_1177_09731296241296204 crossref_primary_10_2147_DDDT_S315060 crossref_primary_10_1016_j_intimp_2024_113011 crossref_primary_10_1111_bph_16283 crossref_primary_10_1007_s10068_024_01753_3 crossref_primary_10_1016_j_ejphar_2021_174660 crossref_primary_10_1016_j_brainres_2023_148664 crossref_primary_10_1002_ptr_7813 crossref_primary_10_1039_D3FO02222F crossref_primary_10_1016_j_intimp_2024_111749 crossref_primary_10_1016_j_neuropharm_2025_110296 crossref_primary_10_1080_09553002_2023_2281515 crossref_primary_10_3390_antiox9030234 crossref_primary_10_3389_fphar_2020_00154 crossref_primary_10_1007_s11011_023_01312_5 crossref_primary_10_1016_j_biopha_2023_114692 crossref_primary_10_1016_j_jad_2023_07_119 crossref_primary_10_1007_s11011_020_00599_y crossref_primary_10_1186_s13020_022_00640_5 crossref_primary_10_1016_j_pmr_2022_04_011 crossref_primary_10_1080_10799893_2021_1900865 crossref_primary_10_3390_ijms23073528 crossref_primary_10_1016_j_jpba_2020_113755 crossref_primary_10_1016_j_neuro_2024_11_006 crossref_primary_10_1016_j_brainres_2023_148678 crossref_primary_10_1016_j_heliyon_2024_e29151 crossref_primary_10_1016_j_neubiorev_2023_105225 crossref_primary_10_1038_s41366_024_01581_9 crossref_primary_10_1016_j_jep_2023_116468 crossref_primary_10_1080_21655979_2021_2001217 crossref_primary_10_1016_j_neuro_2021_05_016 crossref_primary_10_1016_j_jep_2023_116581 crossref_primary_10_1016_j_pnpbp_2022_110693 crossref_primary_10_3389_fnins_2022_1029495 crossref_primary_10_1016_j_arabjc_2024_105668 crossref_primary_10_1016_j_bios_2020_112012 crossref_primary_10_1097_MD_0000000000035793 crossref_primary_10_1007_s12026_022_09295_8 crossref_primary_10_1080_08923973_2023_2165942 crossref_primary_10_30773_pi_2024_0044 crossref_primary_10_1007_s10571_021_01087_2 crossref_primary_10_1016_j_jep_2024_118038 crossref_primary_10_1166_jbmb_2024_2413 crossref_primary_10_3892_etm_2024_12639 crossref_primary_10_3389_fphar_2020_570893 crossref_primary_10_1016_j_phymed_2021_153780 crossref_primary_10_1002_mco2_519 crossref_primary_10_1016_j_bioorg_2022_106005 crossref_primary_10_1016_j_bbr_2021_113463 crossref_primary_10_1016_j_ijbiomac_2022_01_039 crossref_primary_10_1016_j_bcp_2021_114594 crossref_primary_10_3389_fbioe_2022_855022 crossref_primary_10_3389_fpsyt_2020_00557 crossref_primary_10_1007_s11033_024_09852_4 crossref_primary_10_37349_ent_2022_00028 crossref_primary_10_1002_jsfa_11872 crossref_primary_10_71423_aimed_20250103 crossref_primary_10_1007_s11064_023_04026_3 |
| Cites_doi | 10.1016/j.neuron.2018.08.001 10.3390/nu10101351 10.1016/j.bbrc.2014.07.041 10.1016/j.biopha.2008.01.003 10.1124/mol.110.068064 10.1007/s00213-018-4915-7 10.14336/AD.2017.0829 10.1007/s00429-018-1623-3 10.1016/j.bbi.2016.02.022 10.1016/j.bbi.2004.10.003 10.1016/j.intimp.2016.04.012 10.1016/j.it.2005.11.006 10.1021/jf9013263 10.1016/j.ejphar.2017.07.041 10.1111/acps.12698 10.1016/j.jchromb.2008.09.005 10.1186/1742-2094-8-151 10.1016/j.bbi.2017.03.005 10.1002/glia.10274 10.1007/s12035-018-1280-9 10.1007/s11427-015-4861-0 10.1186/1742-2094-11-8 10.4103/1673-5374.217335 10.1016/S0092-8674(00)81663-3 10.1038/s41386-018-0141-6 10.3390/molecules24010110 10.3390/ijms18081666 10.1038/aps.2017.208 10.1016/j.bbrc.2012.02.015 10.1016/j.lfs.2018.05.038 10.1177/0269881117742666 10.1016/j.bbr.2018.07.001 10.1016/j.neulet.2009.12.078 10.1016/j.bbi.2015.12.012 10.1007/s11010-015-2608-7 10.1016/j.neuropharm.2018.06.019 10.1016/j.pnpbp.2013.07.009 10.1038/sj.mp.4002148 10.1016/j.intimp.2018.09.001 10.1155/2018/7254016 10.1016/j.intimp.2014.09.005 10.3389/fphar.2018.00604 10.3109/00207454.2011.591515 10.1016/S0092-8674(00)80595-4 10.1038/npp.2016.125 10.1038/emboj.2010.268 10.1016/j.biopsych.2012.07.005 10.1021/acs.molpharmaceut.7b00029 10.1186/s12974-017-1007-2 10.1016/j.neuroscience.2014.03.039 10.1161/STROKEAHA.107.498212 10.3109/08923973.2012.665461 10.3892/mmr.2017.6751 10.1186/s12974-014-0140-4 10.1016/j.intimp.2017.04.019 10.1016/j.brainres.2018.08.013 10.1186/s12974-017-0865-y 10.1007/s12640-016-9611-y 10.1093/emboj/19.5.989 10.1017/S0033291717002483 10.1186/s12974-017-0823-8 10.1016/j.biopha.2018.11.103 10.3389/fphar.2017.00547 10.1037/a0035302 10.1016/j.bbi.2017.10.025 10.1038/nri.2015.5 10.1038/s41380-018-0076-7 10.1007/s12026-015-8639-z 10.1016/j.bbi.2014.04.007 10.1186/s12974-017-0877-7 10.1074/jbc.273.22.13375 10.1089/ars.2005.7.752 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2019 BioMed Central Ltd. 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2019 |
| Copyright_xml | – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12974-019-1474-8 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database (ProQuest) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1742-2094 |
| EndPage | 21 |
| ExternalDocumentID | oai_doaj_org_article_171f625bac984e0db8ef3559bfbc7d30 PMC6507025 A586555834 31068207 10_1186_s12974_019_1474_8 |
| Genre | Journal Article |
| GeographicLocations | China United States--US |
| GeographicLocations_xml | – name: China – name: United States--US |
| GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: No. 81573701, No. 81703735 – fundername: Heilongjiang Provincial Postdoctoral Science Foundation (CN) grantid: 2017M611958 – fundername: ; grantid: No. 81573701, No. 81703735 – fundername: ; grantid: 2017M611958 |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7T5 7TK 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c560t-8d4e2f12349fa3ab302dad8d5489109b6f58daacbc060d41aec6607e1fff25f73 |
| IEDL.DBID | M48 |
| ISSN | 1742-2094 |
| IngestDate | Wed Aug 27 01:29:17 EDT 2025 Thu Aug 21 13:45:15 EDT 2025 Fri Jul 11 11:23:55 EDT 2025 Fri Jul 25 02:43:28 EDT 2025 Tue Jun 17 21:06:14 EDT 2025 Tue Jun 10 20:22:07 EDT 2025 Thu Jan 02 22:59:24 EST 2025 Tue Jul 01 02:54:30 EDT 2025 Thu Apr 24 22:53:42 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Depression Neuroinflammation TLR4 Baicalin FoxO1 |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c560t-8d4e2f12349fa3ab302dad8d5489109b6f58daacbc060d41aec6607e1fff25f73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-1695-7811 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12974-019-1474-8 |
| PMID | 31068207 |
| PQID | 2227165404 |
| PQPubID | 55345 |
| PageCount | 21 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_171f625bac984e0db8ef3559bfbc7d30 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6507025 proquest_miscellaneous_2231943873 proquest_journals_2227165404 gale_infotracmisc_A586555834 gale_infotracacademiconefile_A586555834 pubmed_primary_31068207 crossref_primary_10_1186_s12974_019_1474_8 crossref_citationtrail_10_1186_s12974_019_1474_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-05-08 |
| PublicationDateYYYYMMDD | 2019-05-08 |
| PublicationDate_xml | – month: 05 year: 2019 text: 2019-05-08 day: 08 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of neuroinflammation |
| PublicationTitleAlternate | J Neuroinflammation |
| PublicationYear | 2019 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | F Lamers (1474_CR2) 2018; 48 Yihe Wang (1474_CR17) 2018; 2018 N Yue (1474_CR57) 2017; 14 M Zhou (1474_CR60) 2015; 62 Minqing Gu (1474_CR43) 2018; 10 JY Sun (1474_CR26) 2016; 36 C Saponaro (1474_CR64) 2012; 34 GM Slavich (1474_CR3) 2014; 140 1474_CR53 L Cui (1474_CR28) 2014; 23 S Deng (1474_CR71) 2019; 110 Y Furukawa-Hibi (1474_CR65) 2005; 7 T Franklin (1474_CR1) 2018; 72 JO Lee (1474_CR63) 1999; 99 P Cheng (1474_CR25) 2017; 8 S Li (1474_CR20) 2017; 815 VN Thakare (1474_CR29) 2018; 32 J Saura (1474_CR52) 2003; 44 K Xu (1474_CR48) 2018; 1698 SA Syed (1474_CR9) 2018; 99 ZQ Zhou (1474_CR22) 2017; 12 A Wagatsuma (1474_CR24) 2016; 412 SYK Fong (1474_CR68) 2017; 14 S-N Kim (1474_CR35) 2011; 121 Shafiq Ur Rehman (1474_CR50) 2018; 56 CE Wright (1474_CR7) 2005; 19 CA Köhler (1474_CR8) 2017; 135 Iciar Gárate (1474_CR13) 2011; 8 I Gárate (1474_CR58) 2013; 73 M Fleshner (1474_CR11) 2017; 42 Y Xu (1474_CR44) 2016; 56 A Santiago (1474_CR49) 2018; 13 JR Caso (1474_CR14) 2008; 39 H Jiang (1474_CR6) 2013; 47 W Chen (1474_CR18) 2017; 8 Z Li (1474_CR27) 2009; 63 Anindya Bhattacharya (1474_CR40) 2018; 43 CY Zhang (1474_CR70) 2018; 64 Y Cheng (1474_CR12) 2016; 53 HY Yu (1474_CR33) 2014; 451 D Zuo (1474_CR21) 2016; 30 Y Song (1474_CR30) 2018; 206 N Matsunaga (1474_CR54) 2011; 79 JC O'Connor (1474_CR41) 2009; 14 X Liu (1474_CR34) 2017; 48 XL Zhu (1474_CR42) 2018; 235 T Maehama (1474_CR62) 1998; 29 1474_CR37 J Nakae (1474_CR66) 2000; 19 Y Sonoda (1474_CR61) 2010; 471 1474_CR39 AH Miller (1474_CR10) 2016; 16 A Fellner (1474_CR38) 2017; 18 MT Song (1474_CR32) 2018; 39 H Zhang (1474_CR46) 2018; 223 Huachao Li (1474_CR72) 2018; 24 R Liang (1474_CR19) 2009; 57 L Chen (1474_CR51) 2015; 58 M Zhao (1474_CR59) 2014; 269 I Gárate (1474_CR16) 2014; 11 Y Pan (1474_CR31) 2014; 41 S Shao (1474_CR36) 2017; 16 D Zhao (1474_CR15) 2017; 14 DR Oh (1474_CR45) 2018; 9 C Zhang (1474_CR5) 2019; 356 H HUANG (1474_CR69) 2008; 874 X Hu (1474_CR47) 2017; 64 SY Kim (1474_CR56) 2012; 419 A Brunet (1474_CR67) 1999; 96 CL Raison (1474_CR4) 2006; 27 W Fan (1474_CR23) 2010; 29 H Dong (1474_CR55) 2014; 11 |
| References_xml | – volume: 99 start-page: 914 year: 2018 ident: 1474_CR9 publication-title: Neuron doi: 10.1016/j.neuron.2018.08.001 – volume: 10 start-page: 1351 issue: 10 year: 2018 ident: 1474_CR43 publication-title: Nutrients doi: 10.3390/nu10101351 – volume: 451 start-page: 467 year: 2014 ident: 1474_CR33 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2014.07.041 – volume: 63 start-page: 120 year: 2009 ident: 1474_CR27 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2008.01.003 – volume: 79 start-page: 34 year: 2011 ident: 1474_CR54 publication-title: Mol Pharmacol doi: 10.1124/mol.110.068064 – volume: 235 start-page: 2177 year: 2018 ident: 1474_CR42 publication-title: Psychopharmacology. doi: 10.1007/s00213-018-4915-7 – volume: 8 start-page: 850 year: 2017 ident: 1474_CR18 publication-title: Aging Dis doi: 10.14336/AD.2017.0829 – volume: 223 start-page: 2243 year: 2018 ident: 1474_CR46 publication-title: Brain Struct Funct doi: 10.1007/s00429-018-1623-3 – volume: 56 start-page: 175 year: 2016 ident: 1474_CR44 publication-title: Brain Behav Immun doi: 10.1016/j.bbi.2016.02.022 – volume: 19 start-page: 345 year: 2005 ident: 1474_CR7 publication-title: Brain Behav Immun doi: 10.1016/j.bbi.2004.10.003 – volume: 36 start-page: 86 year: 2016 ident: 1474_CR26 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2016.04.012 – volume: 27 start-page: 24 year: 2006 ident: 1474_CR4 publication-title: Trends Immunol doi: 10.1016/j.it.2005.11.006 – volume: 57 start-page: 7118 year: 2009 ident: 1474_CR19 publication-title: J Agric Food Chem doi: 10.1021/jf9013263 – volume: 815 start-page: 118 year: 2017 ident: 1474_CR20 publication-title: Eur J Pharmacolol doi: 10.1016/j.ejphar.2017.07.041 – volume: 135 start-page: 373 year: 2017 ident: 1474_CR8 publication-title: Acta Psychiatr Scand doi: 10.1111/acps.12698 – volume: 874 start-page: 77 issue: 1-2 year: 2008 ident: 1474_CR69 publication-title: Journal of Chromatography B doi: 10.1016/j.jchromb.2008.09.005 – volume: 8 start-page: 151 issue: 1 year: 2011 ident: 1474_CR13 publication-title: Journal of Neuroinflammation doi: 10.1186/1742-2094-8-151 – volume: 64 start-page: 180 year: 2017 ident: 1474_CR47 publication-title: Brain Behav Immun doi: 10.1016/j.bbi.2017.03.005 – volume: 44 start-page: 183 year: 2003 ident: 1474_CR52 publication-title: Glia doi: 10.1002/glia.10274 – volume: 56 start-page: 2774 issue: 4 year: 2018 ident: 1474_CR50 publication-title: Molecular Neurobiology doi: 10.1007/s12035-018-1280-9 – volume: 58 start-page: 531 year: 2015 ident: 1474_CR51 publication-title: Sci China Life Sci doi: 10.1007/s11427-015-4861-0 – volume: 11 start-page: 8 year: 2014 ident: 1474_CR16 publication-title: J Neuroinflammation doi: 10.1186/1742-2094-11-8 – volume: 12 start-page: 1625 year: 2017 ident: 1474_CR22 publication-title: Neural Regen Res doi: 10.4103/1673-5374.217335 – volume: 99 start-page: 323 year: 1999 ident: 1474_CR63 publication-title: Cell doi: 10.1016/S0092-8674(00)81663-3 – volume: 43 start-page: 2586 issue: 13 year: 2018 ident: 1474_CR40 publication-title: Neuropsychopharmacology doi: 10.1038/s41386-018-0141-6 – volume: 24 start-page: 110 issue: 1 year: 2018 ident: 1474_CR72 publication-title: Molecules doi: 10.3390/molecules24010110 – volume: 18 start-page: 1666 year: 2017 ident: 1474_CR38 publication-title: Int J Mol Sci doi: 10.3390/ijms18081666 – volume: 39 start-page: 1559 year: 2018 ident: 1474_CR32 publication-title: Acta Pharmacol Sin doi: 10.1038/aps.2017.208 – volume: 419 start-page: 466 year: 2012 ident: 1474_CR56 publication-title: Biochem and Biophys Res Commun doi: 10.1016/j.bbrc.2012.02.015 – volume: 206 start-page: 117 year: 2018 ident: 1474_CR30 publication-title: Life Sci doi: 10.1016/j.lfs.2018.05.038 – volume: 32 start-page: 223 year: 2018 ident: 1474_CR29 publication-title: J Psychopharmacol doi: 10.1177/0269881117742666 – volume: 356 start-page: 348 year: 2019 ident: 1474_CR5 publication-title: Behav Brain Res doi: 10.1016/j.bbr.2018.07.001 – volume: 471 start-page: 20 year: 2010 ident: 1474_CR61 publication-title: Neurosci Lett doi: 10.1016/j.neulet.2009.12.078 – volume: 53 start-page: 207 year: 2016 ident: 1474_CR12 publication-title: Brain Behav Immun doi: 10.1016/j.bbi.2015.12.012 – volume: 412 start-page: 59 year: 2016 ident: 1474_CR24 publication-title: Mol Cell Biochem doi: 10.1007/s11010-015-2608-7 – volume: 13 start-page: 360 year: 2018 ident: 1474_CR49 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2018.06.019 – volume: 47 start-page: 33 year: 2013 ident: 1474_CR6 publication-title: Prog Neuro-Psychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2013.07.009 – volume: 14 start-page: 511 year: 2009 ident: 1474_CR41 publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4002148 – volume: 64 start-page: 175 year: 2018 ident: 1474_CR70 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2018.09.001 – volume: 2018 start-page: 1 year: 2018 ident: 1474_CR17 publication-title: Neural Plasticity doi: 10.1155/2018/7254016 – volume: 23 start-page: 294 year: 2014 ident: 1474_CR28 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2014.09.005 – volume: 9 start-page: 604 year: 2018 ident: 1474_CR45 publication-title: Front Pharmacol doi: 10.3389/fphar.2018.00604 – volume: 121 start-page: 562 year: 2011 ident: 1474_CR35 publication-title: Int J Neurosci doi: 10.3109/00207454.2011.591515 – volume: 96 start-page: 857 year: 1999 ident: 1474_CR67 publication-title: Cell. doi: 10.1016/S0092-8674(00)80595-4 – volume: 42 start-page: 36 year: 2017 ident: 1474_CR11 publication-title: Neuropsychopharmacology. doi: 10.1038/npp.2016.125 – volume: 29 start-page: 4223 year: 2010 ident: 1474_CR23 publication-title: EMBO J doi: 10.1038/emboj.2010.268 – volume: 73 start-page: 32 year: 2013 ident: 1474_CR58 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2012.07.005 – volume: 14 start-page: 2908 year: 2017 ident: 1474_CR68 publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.7b00029 – volume: 14 start-page: 234 year: 2017 ident: 1474_CR15 publication-title: J Neuroinflammation doi: 10.1186/s12974-017-1007-2 – volume: 269 start-page: 93 year: 2014 ident: 1474_CR59 publication-title: Neuroscience doi: 10.1016/j.neuroscience.2014.03.039 – volume: 39 start-page: 1314 year: 2008 ident: 1474_CR14 publication-title: Stroke. doi: 10.1161/STROKEAHA.107.498212 – volume: 34 start-page: 858 year: 2012 ident: 1474_CR64 publication-title: Immunopharmacol Immunotoxicol doi: 10.3109/08923973.2012.665461 – volume: 16 start-page: 1269 year: 2017 ident: 1474_CR36 publication-title: Mol Med Rep doi: 10.3892/mmr.2017.6751 – volume: 11 start-page: 140 year: 2014 ident: 1474_CR55 publication-title: J Neuroinflammation doi: 10.1186/s12974-014-0140-4 – volume: 48 start-page: 30 year: 2017 ident: 1474_CR34 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2017.04.019 – volume: 1698 start-page: 195 year: 2018 ident: 1474_CR48 publication-title: Brain Res doi: 10.1016/j.brainres.2018.08.013 – volume: 14 start-page: 102 year: 2017 ident: 1474_CR57 publication-title: J Neuroinflammation doi: 10.1186/s12974-017-0865-y – volume: 30 start-page: 159 year: 2016 ident: 1474_CR21 publication-title: Neurotox Res doi: 10.1007/s12640-016-9611-y – volume: 19 start-page: 989 year: 2000 ident: 1474_CR66 publication-title: EMBO J doi: 10.1093/emboj/19.5.989 – volume: 48 start-page: 1102 year: 2018 ident: 1474_CR2 publication-title: Psychol Med doi: 10.1017/S0033291717002483 – ident: 1474_CR37 doi: 10.1186/s12974-017-0823-8 – volume: 110 start-page: 602 year: 2019 ident: 1474_CR71 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2018.11.103 – volume: 8 start-page: 547 year: 2017 ident: 1474_CR25 publication-title: Front Pharmacol doi: 10.3389/fphar.2017.00547 – volume: 140 start-page: 774 year: 2014 ident: 1474_CR3 publication-title: Psychiatr Bull doi: 10.1037/a0035302 – volume: 72 start-page: 2 year: 2018 ident: 1474_CR1 publication-title: Brain Behavior and Immunity doi: 10.1016/j.bbi.2017.10.025 – volume: 16 start-page: 22 year: 2016 ident: 1474_CR10 publication-title: Nat Rev Immunol doi: 10.1038/nri.2015.5 – ident: 1474_CR39 doi: 10.1038/s41380-018-0076-7 – volume: 62 start-page: 95 year: 2015 ident: 1474_CR60 publication-title: Immunol Res doi: 10.1007/s12026-015-8639-z – volume: 41 start-page: 90 year: 2014 ident: 1474_CR31 publication-title: Brain Behav Immun doi: 10.1016/j.bbi.2014.04.007 – ident: 1474_CR53 doi: 10.1186/s12974-017-0877-7 – volume: 29 start-page: 13375 year: 1998 ident: 1474_CR62 publication-title: J Biol Chem doi: 10.1074/jbc.273.22.13375 – volume: 7 start-page: 752 year: 2005 ident: 1474_CR65 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2005.7.752 |
| SSID | ssj0032562 |
| Score | 2.647301 |
| Snippet | Baicalin, which is isolated from Radix Scutellariae, possesses strong biological activities including an anti-inflammation property. Recent studies have shown... Background Baicalin, which is isolated from Radix Scutellariae, possesses strong biological activities including an anti-inflammation property. Recent studies... Abstract Background Baicalin, which is isolated from Radix Scutellariae, possesses strong biological activities including an anti-inflammation property. Recent... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 95 |
| SubjectTerms | 1-Phosphatidylinositol 3-kinase AKT protein Analysis Animals Anti-Inflammatory Agents - pharmacology Baicalin Behavior Brain research Central nervous system Central nervous system diseases Complications and side effects Cytokines Depression Depression - etiology Depression - immunology Depression, Mental Drug therapy Enzyme-linked immunosorbent assay Flavonoids - pharmacology Forkhead Box Protein O1 - metabolism Forkhead protein FoxO1 FOXO1 protein Gene expression IL-1β Inflammation Inflammation - metabolism Interleukin 1 Interleukin 6 Kinases Lipopolysaccharides Male Mental depression Mice Mice, Inbred ICR Microglia Microglial cells Molecular modelling Nervous system diseases Neuroinflammation Neuroprotective agents Phosphatidylinositol 3-Kinases - metabolism Phosphorylation Physiological aspects Proto-Oncogene Proteins c-akt - metabolism Psychological Distress - complications Psychological Distress - immunology Risk factors Signal Transduction - drug effects siRNA Testing TLR4 TLR4 protein Toll-Like Receptor 4 - biosynthesis Toll-Like Receptor 4 - drug effects Toll-like receptors Transcription factors Tumor necrosis factor-TNF Tumor necrosis factor-α |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1baxQxFA7SB_FFvDtaJYIgCMPOJZNkHluxVKXqg4W-hSST0MHtbLHbi__FH-t35rLsIOiLb7ubZJnknJzvO8y5MPYaOgCjZ0UKMBYp-L9KrRUVvjrvgBEi9llpR5_l4bH4eFKdbLX6opiwoTzwcHCLXOURHN1ZX2sRssbpEIGRtYvOq6bsvXVg3uRMDTa4BJAX4zvMXMvFBVBNUbRFneYCH_QMhfpi_X-a5C1MmsdLbgHQwT12d2SOfG944vvsVugesNtH47vxh-zXvqUDbztuz8KSMu_BInlfrxJaBMEPSYopnHCIs-FTDOxVSJft98CnhH0-tu7hbXfauj6ii68iX0NhhomwkeEcrjoXPNyMcbQdv2otVgb-9UP5aQHmuACufck5dTy-tj8fseOD99_eHaZj74XUgwOtU92IUETAmqijLa0rs6KxjW7g4IBg1E7GSjfWeuczmTUit8FLmamQxxiLKqryMdvpVl14ynjEX-g6eE19kuD_uUzWeaxBpUIhow8JyyZZGD8WJqf-GEvTOyhamkF8BuIzJD6jE_Z2s-R8qMrxt8n7JODNRCqo3f8ANTOjmpl_qVnC3pB6GLr2eDhvx-wFbJEKaJm9ijJ8K12KhO3OZuK6-vnwpGBmNBcXhhKSKa0sw_CrzTCtpBC4LqwuaQ6spSi1KhP2ZNDHzZbA0SWonEqYmmnqbM_zka497YuJg6Er8N5n_-OQnrM7Bd0xigfVu2xn_eMyvABnW7uX_fX8DdeyQOI priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-0gvgifhutsoIgCMvlY5PdPEkrlqpUfbBwb8t-tsEzOXvXqv-Lf6wzySY2CH273M6GbGZ25jfZ-SDkJcgAKD3NGRhjzgD_C6Y1L-HSWAM2goc-K-3oU3V4zD8sy2X84LaJYZWjTuwVtessfiNfYM4mZt6k_M36B8OuUXi6GltoXCc3sHQZSrVYTg5XAeY8jyeZmawWG7BtAmMuapZx-CFntqgv2f-_Yr5kmeZRk5fM0MEdcjviR7o3MPwuuebbe-TmUTwhv0_-7Gt87U1L9Xe_wvx7wJK0r1oJsgTsH1IVGbjiwFRHx0jYC89WzTdPx7R9Ghv40KY9bUwf10W7QLcgNgMhaEq_Boedcup_xWjall40GmZ6-uV98XEB-HEB1u1zRrHv8U_9-wE5Pnj39e0hix0YmAUktGXScZ8HMG68DrrQpkhzp5104OYAzKhNFUrptLbGplXqeKa9rapU-CyEkJdBFA_JTtu1_jGhAW4ha28ldksCL9CkVZ2FGgCVz6tgfULSkRfKxvLk2CVjpXo3RVZqYJ8C9ilkn5IJeT1NWQ-1Oa4i3kcGT4RYVrv_ozs7UXGXqkxkARxCo20tuU-dkT4AIKtNMFa4Ik3IKxQPhZsfHs7qmMMAS8QyWmqvxDzfUhY8IbszSti0dj48CpiKSmOj_ol4Ql5MwzgTA-Fa350jDehMXkhRJOTRII_TkgCpVwDoRELETFJna56PtM1pX1IccLoA9Pvk6sd6Sm7luHsw3lPukp3t2bl_Bphsa573G-8vo683dA priority: 102 providerName: ProQuest |
| Title | Baicalin ameliorates neuroinflammation-induced depressive-like behavior through inhibition of toll-like receptor 4 expression via the PI3K/AKT/FoxO1 pathway |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31068207 https://www.proquest.com/docview/2227165404 https://www.proquest.com/docview/2231943873 https://pubmed.ncbi.nlm.nih.gov/PMC6507025 https://doaj.org/article/171f625bac984e0db8ef3559bfbc7d30 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFD7aRZr2grgTGJWRkJCQQpPGiZ0HhFa0aYA6JkSlvlm2Y7OIko6uG9t_4cdyTi7VIgZvbW1Hdc85_r5TnwvAS9QBPPQ0DxGMeYj8X4Ra8xTfGmsQI7ivs9Imx9nRlH-cpbMN6NpbtT_g-a2uHfWTmi7nb65-Xr9Dg39bG7zMhueIWYJiKfIw5vhCbsI2ApOghgYTvr5USBDdR-3F5q3LdmEHyU6GmCh6KFUX8__7yL6BWf14yhsAdXgX7rTMku03qnAPNlx1H3Ym7d35A_g91iSQsmL6h5tTZj6yTFbXs8R9o2I0SYwhOuko7oJ1MbKXLpyX3x3rEvpZ29qHldVpaeqIL7bwbIUK1UzEM9SdoSvPOHNXbZxtxS5LjSsdO_mQfBoisxwi7n2OGXVE_qWvH8L08ODr-6Ow7c0QWuRIq1AW3I08wh7PvU60SaJRoQtZoAOEBCQ3mU9lobU1Nsqigsfa2SyLhIu996PUi-QRbFWLyj0B5vERMndWUh8l9A9NlOWxz5FquVHmrQsg6mShbFu4nPpnzFXtwMhMNZJUKElFklQygNfrJWdN1Y7_TR6TgNcTqeB2_cFi-U219qtiEXt0FY22ueQuKox0HqlabryxokiiAF6ReihSVPxyVrfZDbhFKrCl9lPKAE5lwgPY681Ec7b94U7BVGcNihKWKe0swuEX62FaSSFylVtc0Bw8TXkiRRLA40Yf11vq1DoA0dPU3p77I1V5WhcbRwYvkBc__eczn8HuiGyIgkDlHmytlhfuORK1lRnAppiJAWyPD45PvgzqvzsGtUn-AdM6Pcc |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VIgEXxBtDgUUCISFZ8WNtrw8ItUCVkKZwaKXetrvrXWoRnNCkLf0v_AZ-IzN-hFpIvfWWZGctr-b1TXYeAK9QBtDoKe6jM-Y-4v_MV4on-FUbjT6Cu7oqbbKbDvf554PkYA3-dLUwlFbZ2cTaUBczQ_-RD6hmkypvAv5-_tOnqVF0u9qN0GjEYmzPzzBkW7wbfUT-vo6i7U97H4Z-O1XAN-jdl74ouI0cGmyeOxUrHQdRoQpRIHRH15nr1CWiUMpoE6RBwUNlTZoGmQ2dc1Hishifew2uo-MNKNjLDlYBXozwIWpvTkORDhboSzPK8cj9kOMH0fN99YiA_x3BBU_Yz9K84Pa278DtFq-yzUbA7sKare7BjUl7I38ffm8pYnNZMfXDTqneH7Erq7tkouyiuDWlkT6G_ihEBesyb0-tPy2_W9a1CWDtwCBWVkelrvPI2MyxJYppQ4iW2c6XSMiZ_dVm71bstFS407Kvo3g8QLw6QG_6JWQ0Z_lMnT-A_SvhzUNYr2aVfQzM4SNEbo2g6UwYdeogzUOXI4CzUeqM9SDoeCFN2w6dpnJMZR0WiVQ27JPIPknsk8KDt6st86YXyGXEW8TgFSG18a5_mB1_k61VkGEWOgxAtTK54DYotLAOAWCunTZZEQcevCHxkGRs8OWMamsm8IjUtktuJlRXnIiYe7DRo0QjYfrLnYDJ1kgt5D-V8uDlapl2UuJdZWcnRIM2msciiz141Mjj6kioASkCyMyDrCepvTP3V6ryqG5hjnFBhmj7yeWv9QJuDvcmO3JntDt-Crci0iTKNRUbsL48PrHPEA8u9fNaCRkcXrXW_wWrL3V9 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Baicalin+ameliorates+neuroinflammation-induced+depressive-like+behavior+through+inhibition+of+toll-like+receptor+4+expression+via+the+PI3K%2FAKT%2FFoxO1+pathway&rft.jtitle=Journal+of+neuroinflammation&rft.au=Guo%2C+Li-Ting&rft.au=Wang%2C+Si-Qi&rft.au=Su%2C+Jing&rft.au=Xu%2C+Li-Xing&rft.date=2019-05-08&rft.eissn=1742-2094&rft.volume=16&rft.issue=1&rft.spage=95&rft_id=info:doi/10.1186%2Fs12974-019-1474-8&rft_id=info%3Apmid%2F31068207&rft.externalDocID=31068207 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-2094&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-2094&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-2094&client=summon |